Given the relatively low frequency of PALB2 or BARD1 alterations in prostate tumors, completed and on-going clinical trials are unlikely to enroll a sufficient number of PALB2- or BARD1-altered cases to provide the statistical power to determine the impact of alterations on response to PARP inhibitors or other agents. Here, BARD1 is linked to prostate neoplasm.